Stronger safety warning needed for salmeterol

Article

The FDA’s Pediatric Advisory Committee is calling for a strengthened boxed warning on the asthma medication salmeterol (Serevent) to better display the pediatric risks of the drug.

The FDA’s Pediatric Advisory Committee is calling for a strengthened boxed warning on the asthma medication salmeterol (Serevent) to better display the pediatric risks of the drug. The meeting was prompted as a result of nine serious pediatric adverse events (including five patient deaths in children under 16 years old) reported for salmeterol between March 2006 and April 2007. The use of Serevent has declined since reports of asthma-related deaths a few years ago. However, salmeterol is an ingredient in Advair, another asthma drug.

The committee asked the FDA to prominently display a statement in the labeling that recommends use of the drug only as a second-line treatment for asthma. Some members would like to see salmeterol pulled from the market. The panel will meet to review the safety of all drugs in the long-acting beta agonist class in 2008.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Recent Videos
John Browning, MD, provides practical skincare reminders ahead of summer season
Potential downstream benefits of RSV preventive measures, with Octavio Ramilo, MD
Discussing phase 3 data of Panzyga for PANS, with Michael Daines, MD
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Staphylococcus aureus risk in infants and neonatologist considerations with Aaron Milstone, MD
© 2025 MJH Life Sciences

All rights reserved.